Tenax therapeutics to participate in the guggenheim smid cap biotech conference

Chapel hill, n.c., jan. 31, 2025 (globe newswire) -- tenax therapeutics, inc. (nasdaq: tenx) (“tenax therapeutics” or the “company”), a phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that the company will participate in a fireside chat at the guggenheim smid cap biotech conference, which is taking place from february 5-6, 2025, in new york, ny.
SMID Ratings Summary
SMID Quant Ranking